03483nam 2200625 a 450 991096754230332120251116181638.01-61761-457-2(CKB)2550000001042096(EBL)3019248(SSID)ssj0000854109(PQKBManifestationID)12308034(PQKBTitleCode)TC0000854109(PQKBWorkID)10902974(PQKB)10486015(MiAaPQ)EBC3019248(Au-PeEL)EBL3019248(CaPaEBR)ebr10670813(OCoLC)830627853(BIP)28103808(EXLCZ)99255000000104209620091020d2010 uy 0engur|n|---|||||txtccrAMPK-S6K1 signaling pathway as a target for treating hepatic insulin resistance /Sang Geon Kim, Il Je Cho and Hee Yeon Kay1st ed.New York Nova Science Publishersc20101 online resource (69 p.)Hepatology research and clinical developments seriesDescription based upon print version of record.1-60876-693-4 Includes bibliographical references (p. [33]-49) and index.Introduction: Insulin signaling in hepatocytes -- Clinical and preclinical drugs for the treatment of hepatic insulin resistance.Hepatic insulin resistance and altered insulin metabolism, as characterized by the desensitization of hepatic parenchymal cells to insulin, play a role in the pathogenesis of liver disease, particularly resulting in steatosis and steatohepatitis. By the same token, type II diabetic patients are at higher risk for developing liver diseases, including steatosis, hepatitis, cirrhosis, and hepatocellular carcinoma. On the other hand, established liver disease from any cause leads to glucose intolerance and peripheral insulin resistance systemically. The link between insulin resistance and liver pathology reviewed in this book suggests that insulin resistance is closely related with a variety of liver diseases. Recent evidence indicates that the AMP activating protein kinase (AMPK) in conjunction with p70 ribosomal S6 kinase 1 (S6K1) serves as a key signaling pathway regulating insulin-dependent physiological functions; thus, this pathway serves as a target for the therapy of diseases associated with insulin resistance. In this chapter, the regulatory role of the AMPK-S6K1 pathway is discussed in terms of enhancing insulin receptor signaling with insulin receptor substrate-1/2 and phosphatidylinositol phosphate kinase activity, which may contribute to preventing and/or treating insulin resistance in the liver.Hepatology research and clinical developments series.Insulin resistanceMolecular aspecstsLiverDiseasesMolecular aspecstsProtein kinasesInsulin resistanceMolecular aspecsts.LiverDiseasesMolecular aspecsts.Protein kinases.616.3/6207Kim Sang Geon1860971Cho Il Je1860972Kay Hee Yeon1860973MiAaPQMiAaPQMiAaPQBOOK9910967542303321AMPK-S6K1 signaling pathway as a target for treating hepatic insulin resistance4466980UNINA